By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – William Blair initiated coverage of Sequenom today with an Outperform rating, citing the commercial potential of the San Diego-based company's T21 molecular diagnostics test.

Analyst Brian Weinstein estimated in a research note that Sequenom would have 2011 revenues of $54.8 million and 2012 revenues of $78.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.